US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.1099

-0.0049-4.27%

Post-market: 0.11300.0031+2.82%19:59 EDT

Volume:4.47M

Turnover:483.20K

Market Cap:3.61M

PE:-0.07

High:0.1143

Open:0.1137

Low:0.1040

Close:0.1148

Loading ...

Overview Company News Filings

Super League Enterprise (SLE) Reports Q4 Loss, Misses Revenue Estimates

BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive Officer

Super League Enterprise Q4 2024 Adj EPS $(0.29) Misses $(0.26) Estimate, Sales $3.43M Miss $5.50M Estimate

Super League Enterprise Inc - President Matt Edelman Promoted to Role of Chief Executive Officer

THOMSON REUTERS

Super League Enterprise Inc - Qtrly Shr Loss $0.45

THOMSON REUTERS

Super League Enterprise Inc - Ann Hand to Support Strategic Alternative Initiatives as Executive Chair;

THOMSON REUTERS

Press Release: Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues

Dow Dips 150 Points Following Trump's Auto Tariffs, Verint Systems Slides On Q4 Miss: Greed Index Remains In 'Fear' Zone

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts

Super League Enterprise Inc expected to post a loss of 26 cents a share - Earnings Preview

Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Super League Enterprise, Inc. (NASDAQ:SLE) Not Doing Enough For Some Investors As Its Shares Slump 33%

Simply Wall St.

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

EXCLUSIVE: AVID And Super League Bring Learning To Roblox, Helping Teens Build Real-World Skills Through Gaming

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.1099,"timestamp":1750104000000,"preClose":0.1148,"halted":0,"volume":4471324,"hourTrading":{"tag":"盘后","latestPrice":0.113,"preClose":0.1099,"latestTime":"19:59 EDT","volume":286196,"amount":31571.889609,"timestamp":1750118362810},"delay":0,"floatShares":29862399,"shares":32824123,"eps":-1.68411,"marketStatus":"Not Yet Opened","change":-0.0049,"latestTime":"06-16 16:00:00 EDT","open":0.1137,"high":0.1143,"low":0.104,"amount":483200.33504599996,"amplitude":0.089721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.68411,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750147200000},"marketStatusCode":0,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.1148,"preHourTrading":{"tag":"盘前","latestPrice":0.1145,"preClose":0.1148,"latestTime":"09:28 EDT","volume":68434,"amount":7809.56216144,"timestamp":1750080505691},"postHourTrading":{"tag":"盘后","latestPrice":0.113,"preClose":0.1099,"latestTime":"19:59 EDT","volume":286196,"amount":31571.889609,"timestamp":1750118362810},"volumeRatio":0.863792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":29862399,"roa":"-71.33%","roe":"-1235.06%","lyrEps":-2.351262,"volumeRatio":0.863792,"shares":32824123,"dividePrice":0,"high":0.1143,"amplitude":0.089721,"preClose":0.1148,"low":0.104,"week52Low":0.104,"pbRate":"-1.04","psRate":"0.25","week52High":1.64,"institutionHeld":0,"latestPrice":0.1099,"eps":-1.68411,"divideRate":0,"volume":4471324,"delay":0,"ttmEps":-1.68411,"open":0.1137,"prevYearClose":0.6175,"prevWeekClose":0.1148,"prevMonthClose":0.195,"prevQuarterClose":0.235,"fiveDayClose":0.13,"twentyDayClose":0.1775,"sixtyDayClose":0.3463},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522508032","title":"Super League Enterprise (SLE) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522508032","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522508032?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:40","pubTimestamp":1743165602,"startTime":"0","endTime":"0","summary":"Super League Enterprise  came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -28.57%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.54, delivering a surprise of -92.86%.Super League Enterprise , which belongs to the Zacks Gaming industry, posted revenues of $3.43 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 31.48%. This compares to year-ago revenues of $9.51 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Super League Enterprise shares have lost about 35.9% since the beginning of the year versus the S&P 500's decline of -3.2%.While Super League Enterprise has underperformed the market so far this year, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-sle-reports-124002934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LVS","SLE"],"gpt_icon":0},{"id":"2522784175","title":"BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522784175","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522784175?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:49","pubTimestamp":1743162555,"startTime":"0","endTime":"0","summary":"BRIEF-Super League Enterprise President Matt Edelman Promoted To Role Of Chief Executive OfficerMarch 28 (Reuters) - Super League Enterprise Inc SLE.O:SUPER LEAGUE ENTERPRISE INC - PRESIDENT MATT EDEL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2522520479","title":"Super League Enterprise Q4 2024 Adj EPS $(0.29) Misses $(0.26) Estimate, Sales $3.43M Miss $5.50M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520479?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:35","pubTimestamp":1743161727,"startTime":"0","endTime":"0","summary":"Super League Enterprise (NASDAQ:SLE) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 61.33 percent increase over losses of $(0.75) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44533697/super-league-enterprise-q4-2024-adj-eps-0-29-misses-0-26-estimate-sales-3-43m-miss-5-50m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2522520124","title":"Super League Enterprise Inc - President Matt Edelman Promoted to Role of Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520124?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:31","pubTimestamp":1743161503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2522252043","title":"Super League Enterprise Inc - Qtrly Shr Loss $0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2522252043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522252043?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:31","pubTimestamp":1743161503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2522123520","title":"Super League Enterprise Inc - Ann Hand to Support Strategic Alternative Initiatives as Executive Chair;","url":"https://stock-news.laohu8.com/highlight/detail?id=2522123520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522123520?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:31","pubTimestamp":1743161503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nFWN3QB0XJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2522520528","title":"Press Release: Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520528?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues. Ann Hand to Support Strategic Alternative Initiatives as Executive Chair; President Matt Edelman Promoted to the Role of Chief Executive Officer. Renowned Marketing and Advertising Executive Bant Breen Appointed to Board of Directors. SANTA MONICA, Calif., March 28, 2025  -- Super League , a leader in redefining the gaming industry as a media channel, today released fourth quarter and full year 2024 financial results.In an effort to bolster our Board, we are thrilled to appoint Bant Breen as a Director. Bant is a noted marketing and media executive, entrepreneur and academic. Specifically, Bant has spent a vast amount of his career in holding company and operating leadership roles with some of the largest global ad","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","SLE"],"gpt_icon":0},{"id":"2522184495","title":"Dow Dips 150 Points Following Trump's Auto Tariffs, Verint Systems Slides On Q4 Miss: Greed Index Remains In 'Fear' Zone","url":"https://stock-news.laohu8.com/highlight/detail?id=2522184495","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522184495?lang=en_us&edition=fundamental","pubTime":"2025-03-28 14:08","pubTimestamp":1743142102,"startTime":"0","endTime":"0","summary":"U.S. markets closed lower on Thursday due to tariff news, with little change in the CNN Fear &amp; Greed index. S&amp;P 500 and Nasdaq also fell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44529927/dow-dips-150-points-following-trumps-auto-tariffs-verint-systems-slides-on-q4-miss-greed-index-remains-in-fear-zone","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCOM","TQQQ","NVIW.SI","KPLT","MBGAF","BK4077","SLE","PSQ","QID","LU1559883803.SGD","USJW.SI","BK4023","LU0566484027.USD","BK4166","SQQQ","SNX","BK4140","MNQmain","BK4099","BK4122","QLD","POAHF","NQmain","USAW.SI",".IXIC","VRNT","TSYW.SI"],"gpt_icon":1},{"id":"2522330921","title":"Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522330921","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522330921?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:01","pubTimestamp":1743019260,"startTime":"0","endTime":"0","summary":"Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases. Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025. Restructuring and workforce reduction of 34% , including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones. Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029. NKX019 is an allogeneic, off-the-shelf, chimeric antigen receptor  NK-cell therapy candidate engineered to deplete CD19-positive cells in B-cell mediated autoimmune disease. The approach leverages the potential advantages of NK cell therapy, including deep and rapid B-cell killing, a lower risk of cytokine release syndrome and neurotoxicity, the opportunity for pot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkarta-reports-fourth-quarter-full-200100807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","BK4123","BK4077","BK4505","IE00B7SZL793.SGD","BK4230","BK4022","MG","BK4139","CAR","IE00B66KJ199.SGD","SLE","IE00B19Z4B17.USD","NKTX"],"gpt_icon":0},{"id":"2522887962","title":"Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887962?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"Received Clearance from the U.S. Food and Drug Administration  for Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus . Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position. Expanded Pipeline to Include CLYM116, an Anti-APRIL  Monoclonal Antibody for Treatment of IgA Nephropathy . Appointed Perrin Wilson, Ph.D. as Chief Business Officer. Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027. received clearance from the FDA to initiate a Phase 2 clinical trial of. budoprutug in patients with pMN. This open-label, dose-ranging","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4139","BK4199","BK4077","CLYM","SLE"],"gpt_icon":0},{"id":"2522707632","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707632?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Initial data for AlloNK from autoimmune program expected H1 2025. Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025. Strengthened key leadership with cell therapy and autoimmune expertise across organization. Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026. SAN DIEGO, March 24, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","ARTV","R","BK4022","SLE","RA","BK4139","BK4232"],"gpt_icon":0},{"id":"2521205319","title":"Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521205319","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521205319?lang=en_us&edition=fundamental","pubTime":"2025-03-23 20:43","pubTimestamp":1742733837,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc.  stands against other penny stocks with the biggest upside potential.Further insights came from Chris Retzler, portfolio manager for Needham’s Small Cap Growth Fund, who shared his outlook for small-caps on CNBC’sSquawk Boxon January 17, 2025. He noted that small-cap companies are looking for policy certainty, and once the new administration’s direction becomes clearer, we could see growth accelerate. Globally, the EV sector is thriving, even as it faces some hurdles in the United States.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-acet-among-penny-124357821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","ACET","SLE","USJW.SI","BK4139","QID","NVIW.SI","TQQQ",".IXIC","MNQmain","BK4077","PSQ","USAW.SI","SQQQ","NQmain","QLD"],"gpt_icon":1},{"id":"2521402902","title":"Super League Enterprise Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521402902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521402902?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:13","pubTimestamp":1742555586,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of26cents a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0},{"id":"2520437679","title":"Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520437679","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520437679?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"on track with 33 authorized treatment centers as of March 19, 2025,-- Obe-cel MHRA and EMA marketing authorizations expected in H2 2025. -- Initial six patients dosed in Phase 1 dose confirmation trial in Systemic. -- Company to provide clinical development program updates, including plans. for expansion in autoimmune diseases, at R&D investor event to be held on. call participants should pre-register using the link at the bottom of. \"As we begin 2025, we have two key objectives: execute on the commercial launch of AUCATZYL in adult ALL both in the U.S. and entering new markets; and establish the next wave of investments to expand the obe-cel opportunity, advance our clinical pipeline and drive future growth. We look forward to discussing our plans to continue to expand our clinical pipeline and strategy at our R&D event in April.\".  for the treatment of adult patients with relapsed or","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4211","LU1699723380.USD","BK4218","BK4566","SLE","BK4107","LU2355687059.USD","IE00BFMHRM44.USD","LU2463526074.USD","BK4109","LU0985320562.USD","BK4232","BK4139","AUTL","BK4023","BK4181","LU1571399168.USD","SOHO","EBMT","ASH","BK4543","BK4077","LENZ","BK4585","BK4022","BK4533","NICE","ALL"],"gpt_icon":0},{"id":"2520933601","title":"Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520933601","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520933601?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414700,"startTime":"0","endTime":"0","summary":"– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated;","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","BK4534","LU1363072403.SGD","LU1732799900.SGD","LU2271345857.HKD","LU1720051017.SGD","LU0158827781.USD","LU0006306889.USD","BK4127","LU0795875169.SGD","LU2023251221.USD","LU2347655156.SGD","BK4135","LU0158827948.USD","ALMS","LU2111349929.HKD","BK4077","LU2357305700.SGD","LU2028103732.USD","LU2133065610.SGD","BK4516","LU0795875086.SGD","LU2089284900.SGD","LU0106261372.USD","LU0971096721.USD","BK4581","LU0267386448.USD","LU0912757837.SGD","LU1720051108.HKD","LU0106831901.USD","BK4588","BK4007","IE00BKVL7J92.USD","LU2089283258.USD","LU0320765646.SGD","SLE","BK4504","CNS","LU1732800096.USD","BK4585","LU1989772840.SGD","LU0225283273.USD","LU1074936037.SGD","LU0314104364.USD","IE00BZ1G4Q59.USD","LU1548497426.USD","LU1989772923.USD","LU0098860793.USD","LU1162221912.USD"],"gpt_icon":0},{"id":"2520181351","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520181351","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520181351?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth.At its research and development facility at Cambridge Science Park, Conduit is enhancing its IP portfolio and optimize the formulation of its pipeline assets. In the laboratory, the Company is evaluating the assets licensed through the AstraZeneca partnership and other assets of critical interest. Significant progress has also been made in securing intellectual property  protection for Conduit’s lead asset, AZD1656. Recent milestones include the grant of a composition-of-matter patent for the AZD1656 Cocrystals by the Japan Patent Office  and IP Australia, with pending applications at the USPTO and European Patent Office, and other global patent offices, expected to be approved early in the second quarter. In addition, Conduit is actively worki","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-provides-research-development-123000754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1481599808.USD","PRGS","SLE","BK4136","BK4077","BK4585","BK4121","BK4097","BK4588","CDTTW","LU1481600234.SGD","LU2065732104.USD","LU2463526074.USD","IP","LU1487256676.USD","CDT"],"gpt_icon":0},{"id":"2518705315","title":"Super League Enterprise, Inc. (NASDAQ:SLE) Not Doing Enough For Some Investors As Its Shares Slump 33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518705315","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518705315?lang=en_us&edition=fundamental","pubTime":"2025-03-12 02:50","pubTimestamp":1741719043,"startTime":"0","endTime":"0","summary":"Super League Enterprise, Inc. ( NASDAQ:SLE ) shareholders that were waiting for something to happen have been dealt a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4300003-choice1-main-header/1585186588101"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/media/nasdaq-sle/super-league-enterprise/news/super-league-enterprise-inc-nasdaqsle-not-doing-enough-for-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","NVIW.SI","BK4112","IE00B64PRP62.GBP","LU2210150020.SGD","QLD","USAW.SI","SLE","USJW.SI","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","TSYW.SI","NDAQ","NQmain","MNQmain","BK4077","ISBC","BK4211",".IXIC","BK4588","BK4585","QID","PSQ","SQQQ"],"gpt_icon":1},{"id":"2518482877","title":"Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518482877","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518482877?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD. CARLSBAD, Calif., March 11, 2025  -- Exagen Inc. ,a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.Achieved key commercial milestone with completion of 1,000,000th patient tested by AVISE CTD. Featured five abstracts at the 2024 American College of Rheumatology  annual meeting highlighting Exagen’s innovative research on novel T Cell biomarkers for Lupus and sero-negative autoantibodies for rheumatoid arthritis, in addition to a plenary presentation in collaboration with Johns Hopkins University, highlighting a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis patients. Secured New York State Department of Health ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exagen-inc-reports-strong-fourth-120000907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4139","XGN","BK4110","SLE","ACR","RA"],"gpt_icon":0},{"id":"2518748426","title":"EXCLUSIVE: AVID And Super League Bring Learning To Roblox, Helping Teens Build Real-World Skills Through Gaming","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748426","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748426?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:45","pubTimestamp":1741693527,"startTime":"0","endTime":"0","summary":"On Tuesday, AVID  and Super League Enterprise Inc  announced the launch of AVID Creator Planet, an educational adventure on Roblox Corp  for students ages 13+ to learn valuable executive function and durable skills in and out of the classroom.Funded by a grant from the Roblox Community Fund, AVID Creator Planet focuses on practicing durable skills such as problem-solving, critical thinking, collaboration, and communication.Each phase, from planning and construction to adaptation and evaluation, challenges learners to apply these principles in dynamic and interactive scenarios.To bring the AVID Creator Planet learning experience into the classroom, AVID has created a full suite of free resources around the game in AVID Open Access, including step-by-step lessons and all the resources necessary for teachers and students.Set on Equinova, an extraterrestrial planet, Roblox users learn durable skills and practice engineering design through building challenges that use a variety of materials","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-avid-super-league-bring-114527916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4565","LU0348723411.USD","BK4535","BK4551","BK4554","BK4085","AVID","BK4170","BK4588","LU1861559042.SGD","RBLX","BK4547","SLE","LU1861558580.USD","BGSX","BK4585"],"gpt_icon":0},{"id":"2517911392","title":"Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911392","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911392?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis  patient cohort in 1H25. Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25. Initiation of ADI-001 Phase 1 clinical trial patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected in 2Q25; anti-neutrophil cytoplasmic autoantibody  associated vasculitis  patient enrollment expected to be initiated in 2H25. Continuing to advance phase 1 trial of ADI-001 in autoimmune diseases. In November 2024, Adicet announced the dosing of the first patient in the Phase 1 trial evaluating ADI-001 in LN. Enrollment for SLE, SSc, IIM, and SPS patients is expected to commence in the second quarter of 2025, with the initiation of AAV patient enrollment anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-reports-fourth-quarter-210100654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","PRGS","BK4080","BK4231","SITC","CAR","BK4077","IIM","BK4230","ACR","ACET","BK4022","BK4139","BK4110","BK4097","SLE"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":101,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694232000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-06-13","current":-0.226363,"percent":0.703614,"low":-0.555206,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"high":-0.044016,"avg":-0.274466,"sd":0.104139,"marketCap":3532387},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387}],"updateTime":1750143594778}}}